Coming Up Trumps
Four and a half years ago, Schering-Plough was struggling to deal with declining sales and earnings as well as legal and regulatory challenges. Desperately in need of new direction, it found its saviour in Fred Hassan. Julia Puppe spoke with the turnaround ace about playing a poor hand well.
More >>

A Vaccine Gives Marketing Lessons
Beverly Lybrand, Vice President of the HPV Franchise and Gardasil at Merck, explains why the human papillomavirus (HPV) preventative vaccine Gardasil is still picking up steam.
More >>

Technologies of the Future
Dr. Richard Hargreaves, Vice President for Imaging and Dr. Alan Sachs, Vice President of RNA Therapeutics for Merck Research Laboratories talk to NGP’s Rebecca Goozee about new breakaway technologies at Merck Research Laboratories.
More >>

Brilliant BioPharma
Wyeth BioPharma is the fourth largest biotech company in the world, Cavan Redmond and Dr. Michael Kamarck talk to NGP’s Rebecca Goozee about challenges, collaborations and the future of biotechnology.
More >>

The fight against TB
Robert Smith, President of the Eli Lilly and Company Foundation, and Dr. Gail Cassell, Vice President for Scientific Affairs and Distinguished Research Scholar in Infectious Diseases at Eli Lilly, explain the magnitude of the health crisis caused by tuberculosis and the critical global collaboration needed to help halt the spread of the disease in regions of the developing world.
More >>

A new generation of vaccines
Novartis is making major investments to be able to offer novel influenza vaccines. Europe's second-largest pharmaceutical company, the fourth largest in the world, is building a latest-technology production site, aiming to improve production reliability for a potential pandemic. NGP spoke with Dr. Jörg Reinhardt, CEO of Novartis’ division Vaccines and Diagnostics, about the company’s proprietary cell culture technology.
More >>

The only way is up
Novartis has (almost) arrived at the top. The world’s fourth largest pharmaceutical company received Fortune’s accolade of The World’s Most Admired Company.
More >>

The pursuit of productivity
Dr. Steven Paul, EVP for Science and Technology and President of Lilly Research Laboratories, reflects on the overall state of the industry.
More >>

Dedicated to diabetes
Novo Nordisk is a world leader in diabetes care and insulin products. In addition, the Danish company has a leading position in areas such as haemostasis management, growth hormone therapy, and hormone replacement therapy.
More >>

The downsizing solution
Despite 2006 revenues of more than $45 billion (+2 percent), the world’s largest pharmaceutical company is cutting 10,000 jobs as it tries to cut costs by over $2 billion annually.
More >>

Marketing from big pharma to start-up biotech
Having recently made the move from pharmaceutical giant Pfizer to California-based biotech company, Cerimon Pharmaceuticals, Inc.
More >>

Marketing magic at Shire
NGP speaks with Charlotte Sibley, SVP of Global Business Research and Intelligence at Shire Pharmaceuticals, about their innovative practices for applying market research and competitive intelligence to build lasting and successful brands.
More >>

Q&A: Brian Fagen
Brian Fagen is Executive Director of The Society of Pharmaceutical and Biotech Trainers with 30 years of experience in various positions inside and outside of the pharmaceutical industry. He talks to NGP about the role of the SPBT.
More >>

Ask the Expert: Lab-on-a-chip, have it their way or your way?
Has lab-on-a-chip design become pounding your assay design to fit existing structures or can you get a biochip that is your assay design as you developed it? By Stephen F. Malin, CFD Research Corporation
More >>

Highly evolved
How can Amgen continue its impressive revenue growth? By continuing on its course as an “R&D-driven” company, according to Willard Dere, Senior Vice President of Global Development and Chief Medical Officer.
More >>

Executive insight
NGP talks to Genzyme’s Fredric Vinick.
More >>

A new era for MicroRNA
Berta Strulovici, Vice-President Research, Automated Biotechnology Dept, Merck & Co. speaks with NGP, and provides some insight into the recent emergence of MicroRNA.
More >>

Rare dedication
Sigma-Tau Pharmaceuticals specializes in discovering novel therapies for patients suffering with rare diseases. After all, this unique company is keen to stress, ‘there’s no difference between a disease that affects 300 or 300 million people’.
More >>

Six degrees of candidate care
Jonathon Edgley speaks to Lou Manzi of drug giant GlaxoSmithKline about the importance of candidate care.
More >>

The appliance of IT in science
NGP catches up with Geoff Odell, Chairman of the LSIT Global Institute and CIO of the Novartis Genomic Research Institute, to discover how instrumental IT is to the life science drug pipeline.
More >>

Dealing with data: a pharmaceutical imperative
Greg Caressi is Vice President of the Healthcare and Life Sciences group at Frost & Sullivan, serving as the business unit leader for North American and Latin American operations.
More >>

Mapping out the future
Dr Allen Roses, Senior Vice President of Genetics Research at GSK, explains how by understanding our own genetic makeup, the possibility is there to create personalized drugs with greater efficacy and safety.
More >>

Pfizer global R&D: today and tomorrow
Dr John L LaMattina, President of Pfizer Global Research & Development, says we should be looking beyond its disclosed pipeline…
More >>

Thought leader
Wyeth’s Dr Robert Ruffolo has been at the forefront of change in our industry. In this exclusive interview, he explains how and why change is vital to continued success.
More >>

Noninvasive Imaging in Drug Discovery and Development. Where to Begin
More >>

When two heads are better than one
According to PA Consulting’s Jan Malek, R&D president isn’t one job – it’s two. Maybe it’s time to create a new position …
More >>

Breaking new ground
Jerry Moy of Siemens Business Services talks RFID and the pharmaceutical supply chain.
More >>

Made to last
Ensuring the ongoing success of a Business Intelligence program.
More >>

On the record
Talking with Matthew J. Toussant, Ph.D, Vice President, Editorial Operations, CAS.
More >>

Top training tips
Developing staff through innovative learning solutions is key to success.
More >>

Behavior and coaching: a leader’s competitive edge
More >>

“Success is about understanding the nuances of our industry and being customer-centric”
John Potthoff, PhD, is President of Clinical Development, North America, at INC Research.
More >>

Talking with JSS Medical’s Dr John Sampalis
Dr John Sampalis, President and founder of JSS Medical Research Inc.
More >>

Taking pharma forward
To many outside the pharmaceutical industry, the concepts of industry success and meeting patient needs seem incompatible. Billy Tauzin, President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) disagrees.
More >>

One size does not fit all
Judy Hanover, Life Science Insights, on how content management systems in the life sciences are instrumental in supporting complex regulatory compliance requirements and organizing vast sets of information.
More >>

Find them, keep them
Why greater education and outreach is critical to more effective clinical research. Interview with CISCRP?s co-founder Ken Getz.
More >>

The need for speed
Sylva Collins reports on paradigm-changing clinical trials technology.
More >>

New frontiers in drug development
Scott Gottlieb, Deputy Commissioner for Medical and Scientific Affairs at the FDA, gazes into the (very near) future.
More >>

Quality counts
Ali M. Afnan of the FDA and OPS discusses the Government?s Framework for Innovative Pharmaceutical, Development, Manufacturing and Quality Assurance.
More >>